296 related articles for article (PubMed ID: 28276200)
1. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause.
Sarri G; Pedder H; Dias S; Guo Y; Lumsden MA
BJOG; 2017 Sep; 124(10):1514-1523. PubMed ID: 28276200
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
Umland EM
J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
4. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.
Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH
J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145
[TBL] [Abstract][Full Text] [Related]
5. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
[TBL] [Abstract][Full Text] [Related]
6. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice.
Villaseca P
Climacteric; 2012 Apr; 15(2):115-24. PubMed ID: 22148909
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
Handley AP; Williams M
J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis.
Derzko C; Sergerie M; Siliman G; Alberton M; Thorlund K
Menopause; 2016 Mar; 23(3):294-303. PubMed ID: 26382309
[TBL] [Abstract][Full Text] [Related]
9. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause.
Fugate SE; Church CO
Ann Pharmacother; 2004 Sep; 38(9):1482-99. PubMed ID: 15292498
[TBL] [Abstract][Full Text] [Related]
10. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.
Thacker HL
J Womens Health (Larchmt); 2011 Jul; 20(7):1007-16. PubMed ID: 21675874
[TBL] [Abstract][Full Text] [Related]
11. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
12. Symptoms of menopause: hot flushes.
Santoro N
Clin Obstet Gynecol; 2008 Sep; 51(3):539-48. PubMed ID: 18677148
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of nonhormonal drugs on menopausal hot flashes.
Li L; Xu L; Wu J; Dong L; Zhao S; Zheng Q
Eur J Clin Pharmacol; 2016 Sep; 72(9):1051-8. PubMed ID: 27450233
[TBL] [Abstract][Full Text] [Related]
14. Management of Menopause Symptoms with Acupuncture: An Umbrella Systematic Review and Meta-Analysis.
Befus D; Coeytaux RR; Goldstein KM; McDuffie JR; Shepherd-Banigan M; Goode AP; Kosinski A; Van Noord MG; Adam SS; Masilamani V; Nagi A; Williams JW
J Altern Complement Med; 2018 Apr; 24(4):314-323. PubMed ID: 29298078
[TBL] [Abstract][Full Text] [Related]
15. Review: In menopause (intact uterus), estrogen + progestogen, isoflavones, and black cohosh reduce hot flashes.
Maki DG
Ann Intern Med; 2017 Sep; 167(6):JC26. PubMed ID: 28975316
[No Abstract] [Full Text] [Related]
16. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis.
Shams T; Setia MS; Hemmings R; McCusker J; Sewitch M; Ciampi A
Altern Ther Health Med; 2010; 16(1):36-44. PubMed ID: 20085176
[TBL] [Abstract][Full Text] [Related]
19. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis.
Wei D; Chen Y; Wu C; Wu Q; Yao L; Wang Q; Wang XQ; Yang KH
BJOG; 2016 Oct; 123(11):1735-43. PubMed ID: 27062457
[TBL] [Abstract][Full Text] [Related]
20. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.
Carris N; Kutner S; Reilly-Rogers S
Ann Pharmacother; 2014 Oct; 48(10):1343-9. PubMed ID: 25028744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
